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ABSTRACT 
 
Background: Common antimicrobial regimens for treating bacterial vaginosis often cause 
recurrence and bacterial resistance. Previous studies have reported thata combination of 
antimicrobial and probiotic consisting of Lactobacillus spp. is an effective treatment for recurrent 
bacterial vaginosis. Lactobacillus plays an important role in vaginal health byreplacing the 
pathogenic colonies in vagina. This study aimed to determinethe effectiveness of adding probiotic 
toantimicrobial therapeutic for theprevention of  bacterial vaginosis(BV) recurrence. 
Subjects and Method: A systematic review was conducted by searching the following databases: 
PubMed, Science Direct, Web of Science, Springer Link and the Cochrane. The review included 
randomized controlled trials (RCTs) conducted in primary hospitals and private clinics. The Amsel 
criteria and Nugent score were used for diagnosis appraisal of bacterial vaginosis. were included in 
this systematic review consisting of the two types of bacterial vaginosis treatment.  All pooled data 
analyses were based on random-effects models and intention to treat (ITT). Data were analyzed 
using Rev Man 5 software. 
Results: The review included 5 RCTs involving 692 women on reproductive age underwent 
treatment of BV for 5 days or more.The studies showed that combination of probiotic and 
antimicrobial treatment reduced the risk of bacterial vaginosis recurrence a half time compared to 
antimicrobial treatment alone(RR= 0.49; 95% CI= 0.17 to 1.44).  
 
Conclusion: Adding probiotic to antimicrobial regimens is more effective than antimicrobial 
regimens alone for treating bacterial vaginosis recurrence.  
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BACKGROUND 
Vagina and ectocervix provide complex 
habitat for several aerobic and anaerobic 
microorganisms coexisting in a dynamic 
balance for health(Mastromarino et al., 
2013). In this environment, Lactobacillus 
spp are the most dominant bacteria that 
also plays an important role in the main-
tenance of thevaginal tract health (Alioua et 
al., 2016). The imbalance of vaginal 
microbiota includingdecreased amount of 
Lactobacillus may cause vaginal 
inflammation.  
There are millions of vaginitis 
annually, most are caused by bacterial vagi-
nosis (BV) about (40% to 50%), (Vicariotto 
et al., 2014). However, the actual preva-
lence of BV is difficult to determinebecause 
many episodes are asymptomatic and occur 
during the menstrual cycle (Reid and 
Bocking, 2003). 
Bacterial vaginosis is a polymicrobial 
syndrome involving condition that can 
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change the composition of vaginal micro-
organisms. This syndrome is characterized 
by the decrease or absence of Lactobacilli, 
which cause the increase of the vaginal pH 
and the population of pathogenic bacteria 
such as Gardnerella vaginalis, Pretovella 
spp., Bacteroides sp., Mobiluncus spp. or 
genital mycoplasma (Silva et al., 2011). 
Bacterial vaginosis is associated with some 
adverse prognosis including 40%  increase 
in the risk of preterm birth (Stojanovi, et al, 
2012; Vicariotto, et al, 2014), pelvic 
inflammatory disease (Haggerty et al., 
2004), herpes, gonorrhea, and chlamydia 
(Marrazzo et al.,  2007). 
The treatment of BV using antimicro-
bial regimenssuch as oral metronidazole or 
intravaginal clindamycin have been report-
ed to cause recurrences in approximately 
half of the cases. Moreover, the agents 
causing BV such as Gardnerella vaginalis 
and anaerobic bacteria show resistance to 
antimicrobial regimens(Beigi et al., 2004; 
Bradshaw et al., 2006). 
Many studies have considered probio-
tics in addition to antimicrobial regimens 
(Martinez et al., 2009) because antimicro-
bials are not effective, causing recurrent 
infections and bacterial resistance. The 
probiotic containg Lactobacillus is fre-
quently used for BV therapy since it can 
reduce intravaginal pH, thereforeproviding 
a barrier effect against many pathogens as 
well as creating specific molecules such as 
hydrogen peroxide, extracellular proteins, 
and bacteriocin. These molecules kill and 
inhibit the growth of pathogenic bacteria 
(Mastromarino, et al 2013). 
The types of Lactobacilli colonizing 
vagina includeL. crisspatus, L. gasseri, L. 
iners, L. vaginalis, L. jensenii, and L. 
Crispatus that can prevent urogenital 
infection by maintaining a low pH (<4.5) as 
well as producing bacteriostatic and bacte-
ricidal substances. Furthermore, colonizing 
probiotic could be engineered for facili-
tating pathogenic microbicide (Pendharkar 
et al., 2015). 
The combination ofprobiotics and 
antimicrobial regimens or probiotics after 
antimicrobial regimenscan restore Lacto-
bacilli colonization after BV infection or 
after recurrence occurs in order to rebuild 
vaginal homeostasis. Thiscan explain why 
women treated with probiotics have lower 
levels of long-term BV recurrence rate (Ling 
et al., 2013). This study aimed to determine 
the effectiveness of adding probiotic to 
antimicrobial regimens for the prevention 
of  BV recurrence. 
 
SUBJECTS AND METHODS 
This review was conducted in accordance 
with the Preferred Reporting Items for 
Systematic Review and Meta-Analysis from 
the PRISMA Statement (Liberati et al., 
2009). A systematic database searchwas 
performed from 1 to 15 September 2017. 
The databases included PubMed, Science 
Direct, Web of Science, Springer Link and 
the Cochrane Database. The keywords used 
were: probiotic AND metronidazole for 
bacterial vaginosis, probiotic AND anti-
microbial AND randomized controlled trial, 
placebo dosage ANDprobiotic dosage AND 
bacterial vaginosis. 
 
Inclusion criteria 
The inclusion criteria were randomized 
controlled trials (RCTs), either single or 
double-blind RCTs using probiotic contain-
ing Lactobacillus spp. and antimicrobial 
regimens (e.g., metronidazole, tinidazole, 
and clindamycin), or antimicrobial and 
placebo. The subjects included were women 
on reproductive age and the therapy was 
given at least for 5 days. The studies were 
reviewed if the cases of lost to follow-up 
were less than 20%. This review reported 
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articles that published in English from 1994 
until 2017. 
 
Exclusion criteria 
Articles were excluded if the subjects are 
pregnant or post-menopause, intervention 
not relevant with the topic, the outcomes 
for RCTs were not bacterial vaginosis, and 
lack to follow-up. 
 
Primary outcome 
Nugent Score and Amsel criteria were used 
for diagnosing BV. The Nugent score 
criteria is based on the amount per point of 
view of airy morphotype organisms such as 
lactobacillus (given score 4 if not present in 
vaginal swab), Mobiluncus and Gardnerella 
vaginalis (given score 4 if there are >30 per 
point of view). A case with Nugent score of 
7 – 10 is diagnosed with BV. (Bautista et al., 
2016) 
The Amsel criteria include (1) the 
acidity or pH of the vagina exceeds 4.7, (2) 
vaginal discharge color are gray or white. 
(3) release a fish odor when whiff test is 
done (10% potassium hydroxide mixed with 
vaginal discharge), and (4) there are clue 
cells on microscopy of the saline solution 
wet amount. Bacterial vaginosis is diag-
nosed when tha patient presents with least 
3 of those symptoms (Karim and Barakbah, 
2016). 
 
Statistical analysis 
The RevMan 5 meta-analysis program was 
used in this review and the analysis 
included random effect and intention to 
treat (ITT). 
 
RESULTS 
A total of 348 articles were identified 
during initial search. After eliminating 
duplication and implementing the 
exclusion criteria, the remaining 81RCTs 
were further analysed. After careful 
examination of the full-text articles, 
finally 5 articles were included for meta 
analysis(Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Flow diagram of study selection 
Identified through database 
searching (n =  348  ) 
Duplicates removed (n =  25 ) 
 
Records screened (n = 323  ) 
 
Records excluded 
(n = 242  ) 
Not an RCT  =221; The article is not in English = 21 
Full-text articles assessed for 
eligibility (n =  81) 
 
Full-text articles excluded, with reasons 
(n =73 ) 
The outcome is not BV= 22 
The subjects are not  reproductive women = 21 
Intervention  is not relevant with topic = 25 
Limited duration of therapy and lack offolow-up= 9 
 
 
Studies included in qualitative 
synthesis (n = 6 ) 
 
Limited comparison investigation = 1 
 
Studies included in meta-analysis (n = 5  ) 
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The heterogeneity (I2)  of this meta-
analysis is more than 50% so we calculate 
the relative risks (RRs) using random-
ffects model and intention to treat (ITT). 
(Akobeng, 2005). 
1. Per-protocol analysis  
The first analysis is for comparing the 
combination therapy ofprobiotic and 
antimicrobials such as metronidazole, 2% 
clindamycin or 2g tinidazole with the 
combination of antimicrobials and placebo.  
It shows that the combination of probiotic 
and antimicrobial therapy prevents the 
occurrence of bacterial vaginosis 0.49 
although it is not statistically significant 
(RR= 0.49; 95%CI= 0.17 to 1.44). 
 
 Probiotic + 
antimicrobial 
Placebo + 
antimicrobial 
 Risk Ratio Risk Ratio 
Study or 
Subgroup 
Event  Total Event Total Weight M-H, Random 
95% CI 
M-H, Random 95% CI 
Bradshaw   
et al 
9 133 13 135 25.7% 0.70 [ 0.31, 1.59 ] 
 
Heczko et al 22 73 15 81 27.7% 1.63 [ 0.92, 2.89 ] 
Anukam  
et al 
0 49 17 59 10.0% 0.03 [ 0.00, 0.56 ] 
Marcone    
et al 
1 23 2 23 12.5% 0.50 [ 0.05, 5.14 ] 
Martinez  
et al 
4 32 16 32 24.1% 0.25 [ 0.09,  0.67] 
       
Total  
(95% CI) 
 310  330 100.0% 0.49 [ 0.17,  1.44] 
Total events 36  63    
Heterogeneity::  Tau2= 1.00; Chi2=  18.42, df = 4  (p=0.0001); I2= 78% 
Test for overall effect: Z= 1.30  (p= 0.19)   
 
Figure 1.Forest plot  for per protocol analysis between probiotic  
and antimicrobial vs antimicrobial vs placebo 
 
 
 Probiotic + 
antimicrobial 
Placebo + 
antimicrobial 
 Risk Ratio Risk Ratio 
Study or 
Subgroup 
Event  Total Event Total Weight M-H, Random 
95% CI 
M-H, Random 95% 
CI 
Bradshaw   
et al 
9 150 13 150 25.4% 0.69 [ 0.31, 1.57 ] 
 
Heczko et al 22 73 15 81 27.3% 1.63 [ 0.92, 2.89 ] 
Anukam et al 0 65 17 60 10.4% 0.03 [ 0.00, 0.43 ] 
Marcone    
et al 
1 24 2 25 12.9% 0.52 [ 0.05, 5.38 ] 
Martinez  
et al 
4 32 16 32 24.0% 0.25 [ 0.09,  0.67] 
       
Total (95% 
CI) 
 344  348 100.0
% 
0.47 [ 0.15,  1.43] 
Total events 36  63    
Heterogeneity::  Tau2= 1.10; Chi2=  19.73, df = 4  (p=0.0006); I2= 80% 
Test for overall effect: Z= 1.33  (p= 0.19)   
 
Figure 2.Forest plot with ITT 
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2. Intention to treat (ITT) analysis  
The ITT analysis was performed to 
prevent bias in RCTs. The result of 
analysis shows there is no statistically 
significant difference in the outcomes of 
the combination of probiotic and anti-
microbials vs antimicrobials and placebo 
in treating BV (RR= 0.47; 95% CI= 0.15 
to 1.43) which is similar to the results of 
per-protocol analysis.  
Table 1. Summary of included studies evaluating probiotic and metronidazole vs  
metronidazole and placebo 
Author and 
Year 
Setting Total  
follow-
up 
Subjects  
Age 
range 
Inclusion 
Criteria 
Therapy 
I: Intervention 
C: comparison  
Route and 
dosage 
Follow-
Up (days) 
Bradshaw 
et al., 2012 
 
Melbourn
e Sexual 
Health 
Centre 
(MSHC) 
268 
 
18-50 females 
with 
symptoms 
of BV 
I:L. acidophilus 107 
CFU and 400 mg l 
metronidazole 
C: 400 mg 
Metronidazole  and 
Placebo 
 
 
Per Oral 
twice 
Daily 
 
 
 
 180 
Heczko et 
al., 2015 
Nine 
private 
outpatien
t 
gynaecolo
gical 
clinics in 
Poland 
154 18-50 Menstrua
ted 
regularly 
and had 
histories 
of 
recurrent 
BV. 
I: : 500 mg 
metronidazole and 
proVag (L. 
fermentum 57A, L. 
plantarum 57B, and 
L.gasseri 57 C) 
C: 500 mg 
metronidazole and 
plasebo 
Per Oral 
once daily 
Visit II: 
14  
 
Visit III-
IV: 30 
(10 days 
until 3 
months) 
Anukam et 
al., 2006 
Benin 
City 
metropol-
is 
108 18-44 Having 
symptoms 
and signs 
of BV 
I : 500 mg 
metronidazole and 
L. Rhamnosus GR-1 
109CFU and L. 
Reuteri RC-
14109CFU 
C : 500 mg 
metronidazole and 
Placebo 
 
 
 
Per Oral 
twice 
daily 
 
 
 
30  
Marcone et 
al., 2010 
Departm-
ent of 
ObsGyn, 
Sapienza 
Universit
y, Rome 
46 18-45 In the 
diagnosis 
of 
bacterial 
vaginosis 
I: L. rhamnosus 
>4000 CFU and 
500 mg 
metronidazole 
C: 500 mg 
metronidazole 
 
Per Oral 
once daily 
 
 
 
7 
(Martinez 
et al., 
2009) 
Universi-
dade de 
Sao Paulo 
(USP) 
64 16-51 In the 
diagnosis 
of 
bacterial 
vaginosis 
I: L. rhamnosus, 
L.reuteri 108 CFU, 
and 2 g tinidazole  
C: Placebo and 2g 
tinidazole  
 
 
Per Oral 
once daily 
 
 
28 
 
DISCUSSION 
Marcone et al.(2010) reported that 
metronidazole treatment alone without 
complementary Lactobacillus inhibited 
flora vaginal restoration. This resulted in 
BV relapse after 6 months of therapy and 
the recurrence rate increases over time. For 
this reason, it is possible that local 
administration of Lactobacillus spp. could 
be a useful complementary regimen in the 
management of recurrent urinary tract 
infections, especially those associated with 
BV. 
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Lactobacillus rhamnosus exhibits 
adhesion properties on urogenital epi-
thelium, competing with other microorga-
nisms. This bacteria also produce a number 
of factors that inhibit the growth of 
pathogenic bacteria in lower reproductive 
tract. (Falagas, et al 2007) 
Lactobacillus reuteri RC-14 could 
displace Gardnerella vaginalis biofilms in 
vitro.This was not due to pH which 
remained between 4.7 and 5.1 in all 
experiments.  
Lactobacillus crispatus 33820  pro-
duces high amounts of hydrogen peroxide 
(H2O2). The effects of H2O2 will depend 
on the oxidizing ability of the bacterial 
cell.Hydrogen peroxide works alongside 
other organic acids to overcome pathogenic 
bacteria (Martinez et al., 2009). 
However, it is important to note that 
the results of probiotic therapy in BV 
depends on its dosage. The previous studies 
shown that 2x108CFU of L. rhamnosus or 
L. fermentumtwice daily gives a better 
therapeutic effect than1x108CFU once daily 
(Reid , 2001; Bohbot and Cardot, 2012) 
We suggest to give probiotic accord-
ing to thepatient condition as the normal 
flora in vagina is influenced by the age and 
hormonal state. This study excludes pre 
and post menopausal women because the 
BV incidence in women during this period 
increase as a result of decreased estrogen 
hormone that has been associated with a 
decrease in the amount of Lactobacillus in 
the vagina (Cribbyet al, 2008). 
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